Epstein-Barr virus and parvovirus B19 coinfection in a Crohn's disease patient under azathioprine.
Moreira
Teresa
T
Lago
Paula
P
Salgado
Marta
M
Pimentel
Rita
R
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D015725:Fluconazole / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D000077731:Meropenem; D010322:Parvoviridae Infections / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D016732:Parvovirus B19, Human; D012008:Recurrence; D013845:Thienamycins / Q000627:therapeutic use; D055815:Young Adult
D000911:Antibodies, Monoclonal; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D013845:Thienamycins; D016179:Granulocyte Colony-Stimulating Factor; D015725:Fluconazole; D000069285:Infliximab; D000077731:Meropenem; D001379:Azathioprine